Otonomy to Present at the Needham Virtual Healthcare Conference
06 avr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
05 avr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
25 mars 2021 07h30 HE
|
Otonomy, Inc.
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpointPatient enrollment criteria refined to enrich...
Otonomy to Participate in Three Upcoming Investor Conferences
25 févr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
22 févr. 2021 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
17 févr. 2021 07h30 HE
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing lossSupportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
11 févr. 2021 16h17 HE
|
Otonomy, Inc.
OTIVIDEX® Phase 3 trial results in Ménière’s disease expected by end of FebruaryOTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in...
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
04 févr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
05 janv. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
17 déc. 2020 07h00 HE
|
Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing testsA single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to...